Bucyrus International : Cramer thinks the selling in this sector is “misplaced.” These are companies that sell around the world and aren’t held hostage to the U.S. economy. He’s bullish on BUCY.

Amgen : “I still think theres another 3 or 4 more downside points,” Cramer says. Amgen was a key anemia franchise and it still being hurt. In biotech, he likes Gilead – but its Celgene that’s best in show.